Literature DB >> 12036220

Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia.

C C Blyth1, H Darragh, A Whelan, J P O'Shea, M H Beaman, J S McCarthy.   

Abstract

BACKGROUND: While treatment guidelines have been developed to guide the management of Staphylococcus aureus bacteraemia, there is a need to validate these guidelines in different clinical settings and to relate the effect of compliance to clinical outcome. AIMS: To assess the impact of adherence to treatment guidelines on clinical outcome and to explore the role of transoesophageal echocardiography (TOE) in risk stratification.
METHODS: We undertook a 2-year mixed retrospective and prospective study of all cases of S. aureus bacteraemia at Fremantle Hospital, documenting the clinical and microbiological features of each case, the results of echocardiography, adherence with published clinical guidelines and clinical outcome.
RESULTS: Failure to comply with guidelines was observed in 41% (38 of 93) of cases, the majority receiving abbreviated treatment. An increased rate of relapse was observed among patients who received inadequate therapy (5/38 vs 1/55; P= 0.04). Ten of 28 eligible patients underwent TOE and the test led to significant changes in management in two of those cases.
CONCLUSIONS: While non-adherence with clinical guidelines was associated with an increased risk of relapse, the role of TOE in risk stratification was limited by factors including cost, limited acceptance of the test and the need for prolonged therapy for other indications.

Entities:  

Mesh:

Year:  2002        PMID: 12036220     DOI: 10.1046/j.1445-5994.2001.00205.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  [In vitro studies on human ovarian contractility (author's transl)].

Authors:  H Okamura; T Okazaki; A Nakajima
Journal:  Nihon Funin Gakkai Zasshi       Date:  1975-10

2.  Audit of treatment of Staphylococcus aureus bacteraemia.

Authors:  V Wong; R Wariyar; V Weston; W J Olver; E Youngs; A Hussain; N Perera; A Swann
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

3.  Staphylococcus aureus: The persistent pathogen.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2003-11

4.  Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.

Authors:  Yong Pil Chong; Song Mi Moon; Kyung-Mi Bang; Hyun Jung Park; So-Youn Park; Mi-Na Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

5.  Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis.

Authors:  A Incani; C Hair; P Purnell; D P O'Brien; A C Cheng; A Appelbe; E Athan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-17       Impact factor: 3.267

6.  Comparative Sensitivity of Transthoracic and Transesophageal Echocardiography in Diagnosis of Infective Endocarditis Among Veterans With Staphylococcus aureus Bacteremia.

Authors:  Poorani Sekar; James R Johnson; Joseph R Thurn; Dimitri M Drekonja; Vicki A Morrison; Yellapragada Chandrashekhar; Selcuk Adabag; Michael A Kuskowski; Gregory A Filice
Journal:  Open Forum Infect Dis       Date:  2017-02-22       Impact factor: 3.835

7.  Implementing a hospital-wide protocol for Staphylococcus aureus bacteremia.

Authors:  K Bolhuis; L J Bakker; J T Keijer; P J de Vries
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-31       Impact factor: 3.267

8.  Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia.

Authors:  Thomas W van der Vaart; Jan M Prins; Robin Soetekouw; Gitte van Twillert; Jan Veenstra; Bjorn L Herpers; Wouter Rozemeijer; Rogier R Jansen; Marc J M Bonten; Jan T M van der Meer
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.